Analysts See $-0.21 EPS for Heat Biologics, Inc. (HTBX)

July 14, 2018 - By Victoria Pittman

Analysts expect Heat Biologics, Inc. (NASDAQ:HTBX) to report $-0.21 EPS on August, 13.They anticipate $0.69 EPS change or 76.67 % from last quarter’s $-0.9 EPS. After having $-0.75 EPS previously, Heat Biologics, Inc.’s analysts see -72.00 % EPS growth. The stock decreased 1.72% or $0.04 during the last trading session, reaching $2.29. About 342,121 shares traded. Heat Biologics, Inc. (NASDAQ:HTBX) has declined 68.71% since July 14, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $47.65 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

More recent Heat Biologics, Inc. (NASDAQ:HTBX) news were published by: which released: “HC Wainwright Starts Heat Biologics (HTBX) at Buy” on June 26, 2018. Also published the news titled: “Premarket analyst action – healthcare” on July 09, 2018.‘s news article titled: “20 Stocks Moving In Monday’s Pre-Market Session” with publication date: July 09, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.